Letter re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

被引：0
|
作者：
Ding, Qian [1 ]
Guan, Ming-Cheng [1 ]
Zhu, Hong [1 ,2 ]
机构：
[1] Soochow Univ, Dept Med Oncol, Affiliated Hosp 1, Suzhou 215006, Peoples R China
[2] Soochow Univ, Dept Med Oncol, Affiliated Hosp 1, 899,Pinghai Rd, Suzhou 215006, Jiangsu, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2023年 / 192卷
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1016/j.ejca.2023.113263
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies
    Wang, Bi-Cheng
    Kuang, Bo-Hua
    Lin, Guo-He
    TARGETED ONCOLOGY, 2024, 19 (02) : 203 - 212
  • [32] Atezolizumab plus Bevacizumab after first-line multikinase inhibitors for advanced hepatocellular carcinoma: The concept of "drug class change"
    Saitta, Carlo
    Cabibbo, Giuseppe
    DIGESTIVE AND LIVER DISEASE, 2023, 55 (07) : 831 - 832
  • [33] Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies
    Bi-Cheng Wang
    Bo-Hua Kuang
    Guo-He Lin
    Targeted Oncology, 2024, 19 : 203 - 212
  • [34] The Impact of Sequential Therapies after First-Line Systemic Therapies in Unresectable Hepatocellular Carcinoma
    Lee, Shou-Wu
    Lee, Teng-Yu
    Yang, Sheng-Shun
    Huang, Yi-Jie
    Peng, Yen-Chun
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (09)
  • [35] COMPARISON EFFICACY AND SAFETY BETWEEN ATEZOLIZUMAB PLUS BEVACIZUMAB AND LENVATINIB AS FIRST-LINE SYSTEMIC THERAPY FOR HEPATOCELLULAR CARCINOMA: A REAL-WORLD STUDY
    Boonkaya, Sangdao
    Thanapirom, Kessarin
    Siripon, Nipaporn
    Thaimai, Panarat
    Ananchuensook, Prooksa
    Sriphoosanaphan, Supachaya
    Tanasanvimon, Surbpong
    Treeprasertsuk, Sombat
    Komolmit, Piyawat
    GASTROENTEROLOGY, 2024, 166 (05) : S73 - S74
  • [36] First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Chiang, Chi-Leung
    Chan, Sik-Kwan
    Lee, Shing-Fung
    Choi, Horace Cheuk-Wai
    CANCERS, 2021, 13 (05) : 1 - 13
  • [37] Importance of Atezolizumab Plus Bevacizumab Combination Treatment as First-line Therapy for Immunological Changes in Patients With Unresectable Hepatocellular Carcinoma
    Kobayashi, Kojiro
    Nagai, Hidenari
    Matsui, Teppei
    Matsuda, Takahisa
    Higai, Koji
    ANTICANCER RESEARCH, 2023, 43 (10) : 4601 - 4609
  • [38] First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Choi, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S97 - S97
  • [39] Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
    Johira, Yusuke
    Kawaoka, Tomokazu
    Kosaka, Masanari
    Shirane, Yuki
    Miura, Ryoichi
    Murakami, Serami
    Yano, Shigeki
    Amioka, Kei
    Naruto, Kensuke
    Ando, Yuwa
    Kosaka, Yumi
    Kodama, Kenichiro
    Uchikawa, Shinsuke
    Fujino, Hatsue
    Ono, Atsushi
    Nakahara, Takashi
    Murakami, Eisuke
    Okamoto, Wataru
    Yamauchi, Masami
    Imamura, Michio
    Sentani, Kazuhiro
    Oue, Naohide
    Arihiro, Koji
    Kuroda, Shintaro
    Kobayashi, Tsuyoshi
    Ohdan, Hideki
    Chayama, Kazuaki
    Aikata, Hiroshi
    LIVER CANCER, 2022, 11 (02) : 174 - 177
  • [40] First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
    Tella, Sri Harsha
    Kommalapati, Anuhya
    Mahipal, Amit
    Jin, Zhaohui
    BIOMEDICINES, 2022, 10 (06)
12345